Regeneron Pharmaceuticals (NASDAQ:REGN) Hits New 12-Month Low – Time to Sell?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares reached a new 52-week low during trading on Thursday . The company traded as low as $712.30 and last traded at $714.62, with a volume of 907724 shares traded. The stock had previously closed at $740.01.

Analysts Set New Price Targets

Several research analysts recently weighed in on REGN shares. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Royal Bank of Canada lowered their price objective on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. Citigroup assumed coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, November 14th. They issued a “neutral” rating and a $895.00 target price on the stock. Oppenheimer decreased their price target on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Finally, Piper Sandler cut their price objective on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,052.90.

Regeneron Pharmaceuticals Price Performance

The stock has a market capitalization of $77.13 billion, a PE ratio of 17.37, a P/E/G ratio of 2.19 and a beta of 0.08. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The stock’s 50-day moving average is $821.00 and its 200 day moving average is $994.85.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of REGN. Sachetta LLC boosted its position in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares during the last quarter. Adirondack Trust Co. raised its stake in shares of Regeneron Pharmaceuticals by 2.4% during the 3rd quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock worth $453,000 after purchasing an additional 10 shares in the last quarter. UMB Bank n.a. raised its stake in shares of Regeneron Pharmaceuticals by 1.1% during the 3rd quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock worth $955,000 after purchasing an additional 10 shares in the last quarter. Catalyst Financial Partners LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 3.8% during the 2nd quarter. Catalyst Financial Partners LLC now owns 326 shares of the biopharmaceutical company’s stock valued at $343,000 after buying an additional 12 shares during the last quarter. Finally, Trust Co. of Vermont grew its stake in shares of Regeneron Pharmaceuticals by 8.3% in the 3rd quarter. Trust Co. of Vermont now owns 157 shares of the biopharmaceutical company’s stock valued at $165,000 after buying an additional 12 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.